Fungal infections are a leading cause of morbidity and death for hospitalized patients, mainly because they remain difficult to diagnose and to treat. Diseases range from widespread superficial
infections such as vulvovaginal
infections to life-threatening
systemic candidiasis. For systemic
mycoses, only a restricted arsenal of
antifungal agents is available. Commonly used classes of antifungal compounds include
azoles,
polyenes, and
echinocandins. Due to emerging resistance to standard
therapies, significant side effects, and high costs for several antifungals, there is a need for new antifungals in the clinic. In order to expand the arsenal of compounds with antifungal activity, we previously screened a compound library using a cell-based screening assay. A set of novel
benzimidazole derivatives, including (S)-2-(1-aminoisobutyl)-1-(3-chlorobenzyl)benzimidazole (EMC120B12), showed high antifungal activity against several species of pathogenic yeasts, including Candida glabrata and Candida krusei (species that are highly resistant to antifungals). In this study, comparative analysis of EMC120B12 versus
fluconazole and
nocodazole, using transcriptional profiling and
sterol analysis, strongly suggested that EMC120B12 targets Erg11p in the
ergosterol biosynthesis pathway and not microtubules, like other
benzimidazoles. In addition to the marker
sterol 14-methylergosta-8,24(28)-dien-3β,6α-diol, indicating Erg11p inhibition, related
sterols that were hitherto unknown accumulated in the cells during EMC120B12 treatment. The novel
sterols have a 3β,6α-diol structure. In addition to the identification of novel
sterols, this is the first time that a
benzimidazole structure has been shown to result in a block of the
ergosterol pathway.